Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Clinical trial NCT04624633 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04624633
- Sponsor
- Jennifer R. Brown, MD, PhD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-15
- Primary completion
- 2023-12-21
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.